Collegium Pharmaceutical agreed to acquire Corium Therapeutics’ FDA‑approved ADHD product AZSTARYS for $650 million upfront plus up to $135 million in milestones to expand its neuropsychiatric franchise and add an immediate revenue stream. The lead sentence: Collegium is purchasing an on‑market ADHD therapy to accelerate growth and diversify revenue amid a competitive CNS landscape. The deal transfers commercialization rights and should let Collegium leverage its existing CNS commercial infrastructure to drive uptake. Corium exits the asset while retaining other pipeline programs. Analysts expect the acquisition to be evaluated against expected sales ramp, payer placements, and any forthcoming generics or competitor launches. For Corium, the sale monetizes an approved asset and focuses resources on remaining pipeline priorities; for Collegium, AZSTARYS provides an established product to monetize while pursuing longer‑term R&D.